
- Get in Touch with Us
Last Updated: Apr 26, 2025 | Study Period: 2024-2030
DCA, or directional coronary atherectomy, is a minimally invasive surgery that removes blockages in coronary arteries in order to enhance blood flow to the heart muscle and relieve discomfort.
First, a local anesthetic is used to numb the groin region. The doctor next inserts a needle into the femoral artery, which flows down the leg.
The doctor puts a guide wire into the needle before removing it. He replaces it with an introducer, a tubular gadget with two ports used to inject flexible devices into blood vessels, such as catheters.
The initial guidewire is replaced with a finer wire after the introducer is in place. This new wire is used to guide a diagnostic catheter, which is a long flexible tube, into the artery.The second wire is then removed by the doctor.
The doctor injects dye and takes an X-ray with the catheter at the entrance of one of the coronary arteries. If it reveals a curable obstruction, the doctor removes the first catheter and replaces it with a guiding catheter using another guide wire. The wire used for this is then withdrawn and replaced with a finer wire that is advanced over the obstruction.
Another lesion-cutting catheter is also advanced over the obstruction location. A low-pressure balloon is inflated near to the cutter, exposing lesion material to the cutter.When a driving unit is activated, the cutter spins.
The fragments of obstruction it removes are retained in a portion of the catheter called a nose cone until the process is completed.
Rotating the catheter while inflating and deflating the balloon allows the obstruction to be sliced in any direction, resulting in consistent debulking.
A stent may also be inserted. This is a latticed metal scaffold that is placed into the coronary artery to keep it open.
Following the operation, the doctor injects dye and takes an X-ray to examine the arteries for changes. The catheter is then withdrawn, and the surgery is completed.
The cutting blade in directional atherectomy (DA) is oriented towards the artery wall, allowing plaque to be removed when the side cutter comes into contact with the arterial wall.
The plaque is subsequently caught and placed inside the device's nose cone for removal from the body. In the United States, four DA systems are now available: SilverHawk, TurboHawk, and HawkOne by Medtronic, and Pantheris by Avinger.
The SilverHawk Peripheral Plaque Excision System, first version, comprises two disposable components: a portable cutter driver unit with a torque knob and a catheter.
To revolve the cutter, turn the torque knob. The catheter has a conical smooth cutter that engages and cuts the plaque, as well as a nose cone that collects and cuts the plaque.
The Global Directional Atherectomy System Market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Because of its HawkOne Directional Atherectomy System, Medtronic dominates the global market share for directional atherectomy devices used in peripheral artery disease (PAD) procedures.
The FDA has approved Medtronic's TurboHawk Plus Directional Atherectomy System, an improved version of their previous and mostly phased out atherectomy device.
GlobalData expects Medtronic to use its new product to assist market expansion outside of the United States.
HawkOne, SilverHawk, and TurboHawk systems are among Medtronic's offerings. The later devices were Medtronic's first product offerings, before HawkOne was introduced.
HawkOne has since become the device of choice, resulting in very poor utilization of previous systems. Furthermore, both of them have been subjected to several recalls throughout the years.
According to GlobalData, the Peripheral Directional Atherectomy market is expected to be worth based on current growth patterns.
However, the gadgets and treatments are now exclusively popular in the United States, leaving a big worldwide market virtually unexplored.
The clearance of Medtronic's TurboHawk Plus demonstrates the value of diversified product offers in medical device markets.
Medtronic can better manage pricing dynamics and use this to assist market growth in global markets by offering various products in the same market.
Furthermore, the company's varied product range enables it to adapt to patient-specific situations, which will support a rise in atherectomy procedures during PAD treatments.
Peripheral Directional Atherectomy is a competitor method to Boston Scientific's Peripheral Rotational Atherectomy.
Outside of the United States, rotational atherectomy is the most prevalent surgery. It is critical for Medtronic to strengthen its Directional Atherectomy devices in order to compete in the PAD treatments market.
All plaque morphologies, even severe calcium, are treated using the HawkOne device. Cleaning quickly and easily improves the efficiency of technique.
Choose HawkOne to protect a patient's native vasculature and leave future treatment options open if the treatment's objective is to build a tiny channel or maximize luminal gain.
The HawkOne directed atherectomy system is designed for peripheral vascular atherectomy. The HawkOne catheter is approved for use in the treatment of heavily calcified lesions in combination with the SpiderFX embolic protection device. The HawkOne catheter should not be used in the coronary, carotid, iliac, or renal arteries.
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
21 | Product installation rate by OEM, 2023 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2023 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |